Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael Wang(St. Joseph Health System), Simon Rule(AstraZeneca (United Kingdom)), Stephen E. Spurgeon(Oregon Health & Science University), Peter Johnson(Cancer Research UK), John Radford(Manchester Academic Health Science Centre), Stephan Stilgenbauer(Universität Ulm), Peter Martin(Northwestern University), Martin Dreyling(LMU Klinikum), Kristie A. Blum(Emory University), Ranjana H. Advani(Stanford Medicine), Brad S. Kahl(UW Health University Hospital), Jacqueline C. Barrientos(Mount Sinai Medical Center), Ewa Chmielowska(Centrum Onkologii), Jorge Romaguera(The University of Texas MD Anderson Cancer Center), André Goy(Hackensack University Medical Center), Linda Baher(Pharmacyclics (United States)), Michael E. Williams(University of Virginia), Liang Zhang(The University of Texas MD Anderson Cancer Center), Wojciech Jurczak(Jagiellonian University), W Wiktor-Jędrzejczak(Medical University of Warsaw), Dana Lee(Pharmacyclics (United States)), Rebecca Auer(St Bartholomew's Hospital), Mei Cheng(Pharmacyclics (United States)), Darrin M. Beaupre(Pharmacyclics (United States))
Cited by 408
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k